Hydroxyurea Therapy in Thalassemia^a.

LOUKOPOULOS, DIMITRIS; VOSKARIDOU, ERSI; STAMOULAKATOU, ALEXANDRA; PAPASSOTIRIOU, YANNIS; KALOTYCHOU, VASILIKI; LOUTRADI, APHRODITE; COZMA, GABRIEL; TSIARTA, HELENI; PAVLIDES, NIKOS

A bstract: The clinical effectiveness of Hydroxyurea in thalassemia is still controversial. The present paper puts together the authors' experience in two groups of patients with thalassemia intermedia and sickle cell/β-thalassemia treated with varying dosages of hydroxyurea over several months. A third group received hydroxyurea along with recombinant human erythropoietin. Our observations are summarized in that treatment with hydroxyrea results in a significant increase of fetal hemoglobin with no change of the total hemoglobin levels. The drug causes also a considerable increase of the erythrocyte volume and hemoglobin content while the MCHC values remain unchanged. As a rule, and without objective criteria so far, patients state feeling better and having more energy. The authors postulate that this feeling may reflect the significant decrease of ineffective erythropoiesis resulting by the replacement of the poorly hemoglobinized, prematurely dying erythroid progenitor and red cell population by another population of cells with higher hemoglobin content and longer survival, the regeneration of which requires less energy and consumption. As expected, patients with sickle cell/β-thalassemia have also fewer crises and painful episodes. The above findings are in keeping with the few available reports in the literature.

Annals of the New York Academy of Sciences, 1998, Vol 850, Issue 1, p120

0077-8923

Academic Journal

10.1111/j.1749-6632.1998.tb10469.x